Haddadin Yezan Munther 4

What Happened

• Haddadin Yezan Munther, a director of Outlook Therapeutics, acquired 29,000 shares in an open-market purchase on June 2, 2026. The shares were bought at $0.83 each for a total transaction value of $24,145. This was a purchase (not a sale), which some investors view as a positive signal, though the dollar amount is modest.

Key Details

• Transaction type: Open-market purchase (Code P)
• Transaction date: 2026-06-02; Form 4 filed 2026-06-03 (filed the next day)
• Price and quantity: 29,000 shares at $0.83 per share — total $24,145
• Shares owned after transaction: Not specified in the supplied filing
• Footnotes/plan: No 10b5-1 plan, tax withholding, exercise, or other footnotes noted in the provided details

Context

• Director purchases can be interpreted as a signal of confidence by insiders, but this was a relatively small purchase in dollar terms. There’s no indication this was part of a scheduled trading plan or related to option exercises; it appears to be a straightforward open-market buy.